STIMULI RESPONSIVE NANOMEDICINE FOR INFLAMMATORY BOWEL DISEASE: EXPLOITING THE PATHOLOGICAL MICROENVIRONMENT FOR TARGETED DRUG DELIVERY
Introduction IBD is a long-lasting, recurring condition that mainly includes Crohn's disease and ulcerative colitis. It causes ongoing inflammation in the intestines, changes how the immune system works, harms the lining of the gut, and upsets the balance of the gut environment. Even though the way these drugs are given has been improved for treating these diseases, they still aren't very specific to where they're needed, can cause serious side effects, and may lose their effect early on because they don't target the diseased parts of the bowel very precisely. Despite these drawbacks, nanomedicine also helps with stabilizing resistant drugs, targeting the intestines, absorption, and controlled release. Moreover, many pathological changes within IBD relate to abnormal microenvironments (for example, higher levels of ROS, dysfunctional mucus and epithelial barriers, pH changes, abnormal enzymatic activity, disturbance of the redox system and microbial imbalance), providing potential endogenous markers for site-specific delivery of therapeutic agents in the context of stimulus-responsive (e.g. pH, ROS, enzyme, redox, microbiota and multi-responsive) delivery systems. Here, we'll look at the idea of microenvironment-responsive nanomedicine for IBD, covering its design, how it releases drugs, its effects on the disease, and how it can slow progression in the inflamed gut while reducing side effects and overall toxicity, along with discussing important design issues like targeted recognition, nanocarrier stability, biocompatibility, reproducibility, and how to move from preclinical to clinical use. Using natural disease markers to respond specifically fits with new approaches in IBD treatment.
Authors
- Arnab Bagchi
- Pempo Lhamu Bhutia
- Pragya Rani (ORCID: https://orcid.org/0009-0006-7253-9904)
- Rozila Rai
- Priya Pandey
- Nirmika Gurung
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-19
- DOI
- https://doi.org/10.5281/zenodo.24362166
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00